 |
      
|
|
|
|
|
|||||
|
|
January 30, 2003
Neurochem lead investigator awarded NIH grant to support U.S. phase II clinical trials
of Cerebril™. About Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy (CAA)
Hemorrhagic Stroke due to CAA, is characterized by the progressive invasion of the blood
vessel walls in the brain by amyloid fibrils. The blood vessels become brittle and lead to
recurrent strokes and potentially devastating lobar hemorrhages in the brain. The invasion
of the blood vessel wall structure by Amyloid ß (Aß) can result in its
rupture, leading ultimately to Hemorrhagic Stroke. It is considered a major type of stroke
for which there is no effective treatment. While up to 80 percent of lobar hemorrhages
are not fatal the first time, they are frequently recurrent and carry very high morbidity
and mortality rates. About Cerebril™
Cerebril is a small organic molecule that has been designed to modify the course of
Hemorrhagic Stroke due to CAA by interfering with the association between glycosaminoglycans
(GAGs) and Aß amyloid protein in the blood vessels of the brain of patients with CAA.
As part of a "disease modifying" class of drug candidates, Cerebril™ is
expected to act at two levels: first to prevent and stop the formation and deposit of
amyloid fibrils and in binding to Aß, to then inhibit the inflammatory response
associated with amyloid build-up in Hemorrhagic Stroke due to CAA. About Neurochem
Neurochem is a product-driven, specialty pharmaceutical company which offers a new class
of drug candidates to prevent and stop the progression of diseases for which no cure
exists. The Company's strong and growing pipeline will meet unmet medical needs and is
focused on disorders of the central nervous system and amyloid-related diseases. Neurochem's
most advanced product candidate is Fibrillex™, in pivotal Phase II/III clinical
development for the treatment of Secondary Amyloidosis, a fatal kidney disease. Two other
product candidates in Phase II clinical development are Alzhemed™ for the treatment
of Alzheimer's disease and Cerebril™ for Hemorrhagic Stroke due to Cerebral Amyloid
Angiopathy. At the pre-clinical development stage, the Company has two potential products
targeting Diabetes Type 2 and Epileptic Seizures induced by traumatic brain
injury (www.neurochem.com). About the National Institute of Neurological Disorders and Stroke (NINDS)
The NINDS is a component of the National Institutes of Health with the U.S. Department
of Health and Human Services.
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
